Aromatase inhibitors in ovarian cancer: Is there a role?

International Journal of Gynecological Cancer

Volumn 18, Issue 4, 2008, Pages 600-614

  Li, Y F ^a,b   Hu, W ^a   Fu, S Q ^a   Li, J D ^b   Liu, J H ^b   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Aromatase; Aromatase inhibitors; Estrogen; Estrogen receptor; Ovarian cancer

Indexed keywords

14ALPHA HYDROXY 4 ANDROSTENE 3,6,17 TRIONE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; AROMATASE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; EXEMESTANE; EZRIN; FADROZOLE; FORMESTANE; GEFITINIB; LETROZOLE; MYC PROTEIN; NKS01; PACLITAXEL; PLATINUM; PROTEIN BCL 2; SOMATOMEDIN BINDING PROTEIN 5; TAMOXIFEN; TELOMERASE REVERSE TRANSCRIPTASE; TREFOIL PEPTIDE; UNINDEXED DRUG; VIMENTIN; VOROZOLE;

ARTHRALGIA; CANCER PATIENT; CARCINOGENESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DYSPEPSIA; ENZYME INHIBITION; EPIDEMIC; ESTROGEN SYNTHESIS; FATIGUE; FEVER; FRACTURE; GENE EXPRESSION REGULATION; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; LETHARGY; NAUSEA; NONHUMAN; OVARY CANCER; PATIENT SELECTION; POSTMENOPAUSE; PRIORITY JOURNAL; RASH; RECURRENT CANCER; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; VASCULAR DISEASE; VOMITING; WEIGHT GAIN;

AROMATASE; AROMATASE INHIBITORS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOSIS; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; RISK FACTORS;

EID: 47649102822     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01075.x     Document Type: Review

References (195)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66.
2. O'Malley CD, Cress RD, Campleman SL, Leiserowitz GS. Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol 2003 91 : 608 15.
3. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression?. Clin Cancer Res 2004 10 : 7439 49.
4. Trope C, Marth C, Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur J Cancer 2000 36 (Suppl. 4 S59 61.
5. Newhouse ML, Pearson RM, Fullerton JM, Boesen EA, Shannon HS. A case control study of carcinoma of the ovary. Br J Prev Soc Med 1977 31 : 148 53.
6. Annegers JF, Strom H, Decker DG, Dockerty MB, O'Fallon WM. Ovarian cancer: incidence and case-control study. Cancer 1979 43 : 723 9.
7. Hildreth NG, Kelsey JL, LiVolsi VA et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 1981 114 : 398 405.
8. La Vecchia C, Liberati A, Franceschi S. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 1982 69 : 1207.
9. Weiss NS, Lyon JL, Krishnamurthy S et al. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 1982 68 : 95 8.
10. Smith EM, Sowers MF, Burns TL. Effects of smoking on the development of female reproductive cancers. J Natl Cancer Inst 1984 73 : 371 6.
11. Tzonou A, Day NE, Trichopoulos D et al. The epidemiology of ovarian cancer in Greece: a case-control study. Eur J Cancer Clin Oncol 1984 20 : 1045 52.
12. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987 94 : 620 35.
13. Harlow BL, Weiss NS, Roth GJ, Chu J, Daling JR. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 1988 48 : 5849 52.
14. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989 60 : 592 8.
15. Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989 44 : 833 9.
16. Kaufman DW, Kelly JP, Welch WR et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989 130 : 1142 51.
17. Purdie D, Green A, Bain C et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. Int J Cancer 1995 62 : 678 84.
18. Sit AS, Modugno F, Weissfeld JL, Berga SL, Ness RB. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 2002 86 : 118 23.
19. Hartge P, Hoover R, McGowan L, Lesher L, Norris HJ. Menopause and ovarian cancer. Am J Epidemiol 1988 127 : 990 8.
20. Hempling RE, Wong C, Piver MS, Natarajan N, Mettlin CJ. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 1997 89 : 1012 6.
21. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992 136 : 1184 203.
22. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992 136 : 1204 11.
23. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998 92 : 472 9.
24. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000 53 : 367 75.
25. Hoover R, Gray LA Sr., Fraumeni JF Jr. Stilboestrol (diethylstilbestrol) and the risk of ovarian cancer. Lancet 1977 2 : 533 4.
26. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983 71 : 711 6.
27. Rodriguez C, Calle EE, Coates RJ et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1995 141 : 828 35.
28. Lacey JV Jr., Mink PJ, Lubin JH et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002 288 : 334 41.
29. Riman T, Dickman PW, Nilsson S et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002 94 : 497 504.
30. Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology 2004 15 : 100 4.
31. Glud E, Kjaer SK, Thomsen BL et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 2004 164 : 2253 9.
32. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Berchuck A. Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 2005 193 : 76 82.
33. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001 285 : 1460 5.
34. Lacey JV Jr., Brinton LA, Leitzmann MF et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006 98 : 1397 405.
35. Negri E, Tzonou A, Beral V et al. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 1999 80 : 848 51.
36. Polychronopoulou A, Tzonou A, Hsieh CC et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 1993 55 : 402 7.
37. Parazzini F, La Vecchia C, Negri E, Villa A. Estrogen replacement therapy and ovarian cancer risk. Int J Cancer 1994 57 : 135 6.
38. Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 1996 63 : 254 7.
39. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 1996 67 : 327 32.
40. Langdon SP, Gabra H, Bartlett JM et al. Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. Clin Cancer Res 1998 4 : 2245 51.
41. Rodriguez GC, Walmer DK, Cline M et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998 5 : 271 6.
42. Purdie DM, Bain CJ, Siskind V et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 1999 81 : 559 63.
43. Nash JD, Ozols RF, Smyth JF, Hamilton TC. Estrogen and anti-estrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet Gynecol 1989 73 : 1009 16.
44. Langdon SP, Hirst GL, Miller EP et al. The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol 1994 50 : 131 5.
45. Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H. Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 1992 75 : 1497 502.
46. Wimalasena J, Meehan D, Dostal R et al. Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Oncol Res 1993 5 : 325 37.
47. Sawada M, Terada N, Wada A et al. Estrogen- and androgen-responsive growth of human ovarian adenocarcinoma heterotransplanted into nude mice. Int J Cancer 1990 45 : 359 63.
48. Langdon SP, Crew AJ, Ritchie AA et al. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. Eur J Cancer 1994 30A : 682 6.
49. Salvo VA, Boue SM, Fonseca JP et al. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res 2006 12 : 7159 64.
50. Jabara AG. Canine ovarian tumours following stiboestrol administration. Aust J Exp Biol Med Sci 1959 37 : 549 65.
51. Jabara AG. Induction of canine ovarian tumours by diethylstilboestrol and progesterone. Aust J Exp Biol Med Sci 1962 40 : 139 52.
52. Owen NV, Pierce EC, Anderson RC. Papillomatous growths on internal genitalia of bitches administered the synthetic estrogen trans-4,4'-dimethyl-,'- diethylstilbene. Toxicol Appl Pharmacol 1972 21 : 582 5.
53. Bai W, Oliveros-Saunders B, Wang Q, Acevedo-Duncan ME, Nicosia SV. Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cell Dev Biol Anim 2000 36 : 657 66.
54. Silva EG, Tornos C, Deavers M et al. Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation. Gynecol Oncol 1998 71 : 240 6.
55. Kommoss F, Pfisterer J, Thome M et al. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992 47 : 317 22.
56. Rao BR, Slotman BJ. Endocrine factors in common epithelial ovarian cancer. Endocr Rev 1991 12 : 14 26.
57. Munstedt K, Steen J, Knauf AG et al. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 2000 89 : 1783 91.
58. Geisler JP, Wiemann MC, Miller GA, Geisler HE. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary. Gynecol Oncol 1996 60 : 424 7.
59. Abu-Jawdeh GM, Jacobs TW, Niloff J, Cannistra SA. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol 1996 60 : 301 7.
60. Green S, Walter P, Greene G et al. Cloning of the human oestrogen receptor cDNA. J Steroid Biochem 1986 24 : 77 83.
61. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996 93 : 5925 30.
62. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996 392 : 49 53.
63. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005 11 : 865s 70s.
64. McInerney EM, Weis KE, Sun J, Mosselman S, Katzenellenbogen BS. Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 1998 139 : 4513 22.
65. Pujol P, Rey JM, Nirde P et al. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998 58 : 5367 73.
66. Brandenberger AW, Tee MK, Lee JY, Chao V, Jaffe RB. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. J Clin Endocrinol Metab 1997 82 : 3509 12.
67. Hillier SG, Anderson RA, Williams AR, Tetsuka M. Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells. Mol Hum Reprod 1998 4 : 811 5.
68. Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 1998 83 : 1025 8.
69. Matthews J, Gustafsson JA. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 2003 3 : 281 92.
70. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004 11 : 537 51.
71. Skliris GP, Munot K, Bell SM et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003 201 : 213 20.
72. Hopp TA, Weiss HL, Parra IS et al. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004 10 : 7490 9.
73. Chu S, Mamers P, Burger HG, Fuller PJ. Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. J Clin Endocrinol Metab 2000 85 : 1200 5.
74. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A 1999 96 : 5722 7.
75. Fujimoto J, Hirose R, Sakaguchi H, Tamaya T. Clinical significance of expression of estrogen receptor alpha and beta mRNAs in ovarian cancers. Oncology 2000 58 : 334 41.
76. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005 23 : 1616 22.
77. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 2005 12 : 851 66.
78. Dobrzycka KM, Townson SM, Jiang S, Oesterreich S. Estrogen receptor corepressors - a role in human breast cancer? Endocr Relat Cancer 2003 10 : 517 36.
79. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005 96 : 671 7.
80. Clinton GM, Rougeot C, Derancourt J et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc Natl Acad Sci U S A 1996 93 : 316 20.
81. Moll F, Katsaros D, Lazennec G et al. Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene 2002 21 : 1097 107.
82. Roger P, Pujol P, Lucas A, Baldet P, Rochefort H. Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors. Am J Pathol 1998 153 : 1579 88.
83. Hua W, Christianson T, Rougeot C, Rochefort H, Clinton GM. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol 1995 55 : 279 89.
84. Losch A, Schindl M, Kohlberger P et al. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol 2004 92 : 545 52.
85. Chien CH, Wang FF, Hamilton TC. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol 1994 99 : 11 9.
86. Chen CH, Shen J, Lee WJ, Chow SN. Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer. Int J Gynecol Cancer 2005 15 : 878 83.
87. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 2001 142 : 2351 60.
88. Kaern J, Aghmesheh M, Nesland JM et al. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer 2005 15 : 1014 22.
89. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001 7 : 1661 8.
90. Kimura A, Ohmichi M, Kawagoe J et al. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 2004 23 : 4505 15.
91. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecol Oncol 2005 98 : 396 402.
92. Song J, Fadiel A, Edusa V et al. Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett 2005 220 : 57 65.
93. Moilanen J, Lassus H, Leminen A et al. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol 2003 90 : 273 81.
94. Gao N, Nester RA, Sarkar MA. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells. Toxicol Appl Pharmacol 2004 196 : 124 35.
95. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003 17 : 792 803.
96. Kelley KM, Rowan BG, Ratnam M. Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Res 2003 63 : 2820 8.
97. Toffoli G, Cernigoi C, Russo A et al. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997 74 : 193 8.
98. Ding JX, Feng YJ, Yao LQ et al. The reinforcement of invasion in epithelial ovarian cancer cells by 17 beta-Estradiol is associated with up-regulation of Snail. Gynecol Oncol 2006 103 : 623 30.
99. Mukherjee K, Syed V, Ho SM. Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene 2005 24 : 4388 400.
100. Scott IS, Heath TM, Morris LS et al. A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens. Br J Cancer 2004 90 : 1583 90.
101. Li DR, Li L, Zhang W, Wang LM, Zhang JQ. Study on the expression and mutation of cadherin 6 gene in human ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi 2004 39 : 616 9.
102. Gery S, Xie D, Yin D et al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 2005 11 : 7243 54.
103. van Niekerk CC, Boerman OC, Ramaekers FC, Poels LG. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas. Am J Pathol 1991 138 : 455 63.
104. Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol 2002 117 : 944 51.
105. Franke FE, Von Georgi R, Zygmunt M, Munstedt K. Association between fibronectin expression and prognosis in ovarian carcinoma. Anticancer Res 2003 23 : 4261 7.
106. Nakopoulou L, Stefanaki K, Janinis J, Mastrominas M. Immunohistochemical expression of placental alkaline phosphatase and vimentin in epithelial ovarian neoplasms. Acta Oncol 1995 34 : 511 5.
107. Cai Z, Li YF, Liu FY et al. The expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer. Chin J Cancer 2007 26 : 312 7.
108. Wiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer 2006 16 : 210 8.
109. Bardin A, Moll F, Margueron R et al. Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology 2005 146 : 760 8.
110. Sakuma M, Akahira J, Suzuki T et al. Expression of estrogen-responsive finger protein (Efp) is associated with advanced disease in human epithelial ovarian cancer. Gynecol Oncol 2005 99 : 664 70.
111. O'Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol 2004 18 : 1859 75.
112. Wang DY, Fulthorpe R, Liss SN, Edwards EA. Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol 2004 18 : 402 11.
113. Seth P, Krop I, Porter D, Polyak K. Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene 2002 21 : 836 43.
114. Liehr JG. Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 1997 6 : 3 10.
115. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000 21 : 40 54.
116. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000 27 : 75 93.
117. Russo J, Hasan Lareef M, Balogh G, Guo S, Russo IH. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 2003 87 : 1 25.
118. Tsai EM, Wang SC, Lee JN, Hung MC. Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res 2001 61 : 8390 2.
119. Guo RX, Wei LH, Tu Z et al. 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem Mol Biol 2006 99 : 9 18.
120. Mabuchi S, Ohmichi M, Kimura A et al. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Endocrinology 2004 145 : 1302 13.
121. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005 365 : 60 2.
122. Means GD, Kilgore MW, Mahendroo MS, Mendelson CR, Simpson ER. Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. Mol Endocrinol 1991 5 : 2005 13.
123. Kamat A, Mendelson CR. Identification of the regulatory regions of the human aromatase P450 (CYP19) gene involved in placenta-specific expression. J Steroid Biochem Mol Biol 2001 79 : 173 80.
124. Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003 30 : 3 11.
125. Sasano H, Uzuki M, Sawai T et al. Aromatase in human bone tissue. J Bone Miner Res 1997 12 : 1416 23.
126. Simpson ER, Zhao Y, Agarwal VR et al. Aromatase expression in health and disease. Recent Prog Horm Res 1997 52 : 185 213 discussion 13-4.
127. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 2005 23 : 1636 43.
128. de Jong PC, Blijham GH. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women. Neth J Med 1999 55 : 50 8.
129. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 349 : 1793 802.
130. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001 7 : 2620 35.
131. Papadimitriou CA, Markaki S, Siapkaras J et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004 66 : 112 7.
132. Bowman A, Gabra H, Langdon SP et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002 8 : 2233 9.
133. Miller WR. Aromatase inhibitors-where are we now? Br J Cancer 1996 73 : 415 7.
134. Takanishi GC, Borst CA. A New class of hormonal modulators for the treatment of breast cancer. Women's Health Prim Care 2001 4 : 368 72.
135. Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996 74 : 1286 91.
136. Plourde PV, Dyroff M, Dowsett M et al. ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 1995 53 : 175 9.
137. Trunet PF, Bhatnagar AS, Chaudri HA, Hornberger U. Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. Acta Oncol 1996 35 (Suppl. 5 15 8.
138. Lonning PE. Comparison between aromatase inhibitors and sequential use. J Steroid Biochem Mol Biol 2003 86 : 275 82.
139. Geisler J, Lien EA, Ekse D, Lonning PE. Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 1997 63 : 53 8.
140. Santen RJ, Demers LM, Adlercreutz H et al. Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocrinol Metab 1989 68 : 99 106.
141. Labrie F. Intracrinology. Mol Cell Endocrinol 1991 78 : C113 8.
142. Labrie F, Belanger A, Simard J, Van L-T, Labrie C. DHEA and peripheral androgen and estrogen formation: intracinology. Ann N Y Acad Sci 1995 774 : 16 28.
143. Heinonen PK, Koivula T, Rajaniemi H, Pystynen P. Peripheral and ovarian venous concentrations of steroid and gonadotropin hormones in postmenopausal women with epithelial ovarian tumors. Gynecol Oncol 1986 25 : 1 10.
144. Kitayama S, Nakano R. Peripheral and ovarian venous concentrations of estradiol and progesterone in postmenopausal women with "non- endocrine" ovarian tumors. Acta Obstet Gynecol Scand 1990 69 : 245 8.
145. Lindgren PR, Backstrom T, Cajander S et al. The pattern of estradiol and progesterone differs in serum and tissue of benign and malignant ovarian tumors. Int J Oncol 2002 21 : 583 9.
146. Slotman BJ, Kuhnel R, Rao BR et al. Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival. Gynecol Oncol 1989 33 : 76 81.
147. Kitawaki J, Noguchi T, Yamamoto T et al. Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours. Anticancer Res 1996 16 : 91 7.
148. Kuhnel R, Delemarre JF, Rao BR, Stolk JG. Correlation of aromatase activity and steroid receptors in human ovarian carcinoma. Anticancer Res 1986 6 : 889 92.
149. Cunat S, Rabenoelina F, Daures JP et al. Aromatase expression in ovarian epithelial cancers. J Steroid Biochem Mol Biol 2005 93 : 15 24.
150. Kaga K, Sasano H, Harada N et al. Aromatase in human common epithelial ovarian neoplasms. Am J Pathol 1996 149 : 45 51.
151. Noguchi T, Kitawaki J, Tamura T et al. Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women. J Steroid Biochem Mol Biol 1993 44 : 657 60.
152. Thompson MA, Adelson MD, Kaufman LM, Marshall LD, Coble DA. Aromatization of testosterone by epithelial tumor cells cultured from patients with ovarian carcinoma. Cancer Res 1988 48 : 6491 7.
153. Means GD, Mahendroo MS, Corbin CJ et al. Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J Biol Chem 1989 264 : 19385 91.
154. Harada N, Utsumi T, Takagi Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci U S A 1993 90 : 11312 6.
155. Bulun SE, Sebastian S, Takayama K et al. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol 2003 86 : 219 24.
156. Mahendroo MS, Mendelson CR, Simpson ER. Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J Biol Chem 1993 268 : 19463 70.
157. Zhao Y, Mendelson CR, Simpson ER. Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. Mol Endocrinol 1995 9 : 340 9.
158. Zhou C, Zhou D, Esteban J et al. Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 1996 59 : 163 71.
159. Bulun SE, Noble LS, Takayama K et al. Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol 1997 61 : 133 9.
160. Harada N. A unique aromatase (P-450AROM) mRNA formed by alternative use of tissue-specific exons 1 in human skin fibroblasts. Biochem Biophys Res Commun 1992 189 : 1001 7.
161. Sebastian S, Takayama K, Shozu M, Bulun SE. Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue. Mol Endocrinol 2002 16 : 2243 54.
162. Jenkins C, Michael D, Mahendroo M, Simpson E. Exon-specific northern analysis and rapid amplification of cDNA ends (RACE) reveal that the proximal promoter II (PII) is responsible for aromatase cytochrome P450 (CYP19) expression in human ovary. Mol Cell Endocrinol 1993 97 : R1 6.
163. Bulun SE, Rosenthal IM, Brodie AM et al. Use of tissue-specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads. J Clin Endocrinol Metab 1994 78 : 1616 21.
164. Sasano H, Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev 1998 19 : 593 607.
165. Okubo T, Mok SC, Chen S. Regulation of aromatase expression in human ovarian surface epithelial cells. J Clin Endocrinol Metab 2000 85 : 4889 99.
166. Macdiarmid F, Wang D, Duncan LJ et al. Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha. Mol Cell Endocrinol 1994 106 : 17 21.
167. Richards JA, Petrel TA, Brueggemeier RW. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol 2002 80 : 203 12.
168. Chen S, Ye J, Kijima I, Kinoshita Y, Zhou D. Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J Steroid Biochem Mol Biol 2005 95 : 17 23.
169. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture. J Steroid Biochem Mol Biol 1997 61 : 203 10.
170. Zhou D, Chen S. Characterization of a silencer element in the human aromatase gene. Arch Biochem Biophys 1998 353 : 213 20.
171. Zhou D, Chen S. Identification and characterization of a cAMP-responsive element in the region upstream from promoter 1.3 of the human aromatase gene. Arch Biochem Biophys 1999 371 : 179 90.
172. Jin T, Zhang X, Li H, Goss PE. Characterization of a novel silencer element in the human aromatase gene PII promoter. Breast Cancer Res Treat 2000 62 : 151 9.
173. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996 137 : 5739 42.
174. Richards JA, Brueggemeier RW. Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab 2003 88 : 2810 6.
175. Brueggemeier RW, Quinn AL, Parrett ML et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999 140 : 27 35.
176. Brueggemeier RW, Diaz-Cruz ES, Li PK et al. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol 2005 95 : 129 36.
177. Diaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005 90 : 2563 70.
178. Davies G, Martin LA, Sacks N, Dowsett M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 2002 13 : 669 78.
179. Miyoshi Y, Kim SJ, Akazawa K et al. Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer
180. Hu Y, Ghosh S, Amleh A et al. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 2005 24 : 8343 8.
181. Sasano H, Sato S, Ito K et al. Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer 1999 6 : 197 204.
182. Chen D, Hackl W, Ortmann O, Treeck O. Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro. Anticancer Drugs 2004 15 : 55 61.
183. Braun DP, Crist KA, Shaheen F et al. Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity. Am J Surg 2005 190 : 570 1.
184. del Carmen MG, Fuller AF, Matulonis U et al. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol 2003 91 : 596 602.
185. Krasner CN, Debernardo RL, Findley M et al. Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer. Proc Am Soc Clin Oncol 2005 Abstract #5063.
186. Gourley C, Smyth JF, Mackean M et al. Phase II study of letrozole in estrogen receptor (ER) positive relapsed epithelial ovarian cancer (EOC). J Clin Oncol (2006 ASCO Annual Meeting Proceedings, Atlanta, GA) 2006 24 (Pt I Suppl. 18 Abstract #5025.
187. Verma S, Alhayki M, Le T et al. Phase II study of exemestane (E) in refractory ovarian cancer (ROC). J Clin Oncol (2006 ASCO Annual Meeting, Atlanta, GA) 2006 24, Abstract #5026.
188. Tchekmedyian NS, Liem AK, Quan ET, Burtzo DM, Ucar K. Aromatase inhibitor therapy for estrogen receptor positive ovarian cancer. J Clin Oncol (2006 ASCO Annual Meeting Proceedings, Atlanta, GA) 2006 24 : No. 185 (Abstract 15038).
189. Kavanagh JJ, Hu W, Fu SQ et al. Anti-tumor activity of letrozole in patients with recurrent advanced low malignant potential or low grade serous ovarian tumors. J Clin Oncol (2007 ASCO Annual Meeting Proceedings, Chicago, IL) 2007 25 : No. 185 (Abstract 5582).
190. Lee EJ, Deavers MT, Hughes JI, Lee JH, Kavanagh JJ. Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: response to hormone therapy. Int J Gynecol Cancer 2006 16 (Suppl. 1 295 9.
191. Johnston SR. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 2005 11 : 889s 99.
192. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991 9 : 389 93.
193. Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995 13 : 1584 8.
194. Tangjitgamol S, See HT, Manusirivithaya S et al. Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Int J Gynecol Cancer 2004 14 : 804 14.
195. See HT, Freedman RS, Kudelka AP et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005 15 : 209 16.